Minervax: Funding, Investors & Team (Sep 2026)
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Minervax has raised $111M across 2 funding rounds on record, the most recent an undisclosed round of $57.4M announced in Oct 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Minervax Company Profile and Key Stats
Latest funding round on record: Oct 2023.
Minervax Funding Rounds
Minervax raised $53.3M in an undisclosed round announced in Dec 2022.
10 months later, an undisclosed round of $57.4M was announced in Oct 2023.
Minervax Founders and Leadership Team
No contact details are on record for this team yet.
Minervax Funding Compared to Other Biotechnology Startups
Minervax's latest round of $57.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Minervax in Biotechnology and Hellerup
Companies Similar to Minervax
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several…
Alcolase is a Danish life science start-up that specializes in alcohol flushing.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on…
ENZIDIA is unleashing the biomanufacturing revolution with an enzyme acceleration revolution
Gefjon Pharma is a biopharmaceutical company focused on developing innovative solutions to combat…
Synuca Therapeutics focused on developing innovative therapies for neurological disorders, particularly…
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The…
Pioneering new sustainable bio-based ingredients
Muna Therapeutics is a private biopharmaceutical company that discovers and develops therapies that slow or…
EvodiaBio is a company in the bio-industrial sector that develops eco-friendly fragrances for the food and…
Fida Biosystems is a technology that provides the detection and characterization of proteins and…
Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived…
Minervax Funding FAQs
What does Minervax do?
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
How much funding has Minervax raised?
Minervax has raised $111M across 2 rounds on record. The most recent is an undisclosed round of $57.4M announced in Oct 2023.
When did Minervax last raise funding?
Minervax's most recent funding round on record is an undisclosed round of $57.4M, announced in Oct 2023.
Who is the CEO of Minervax?
Per Fischer is listed as CEO at Minervax.
Where is Minervax headquartered?
Minervax is based in Hellerup, Hovedstaden, Denmark.
How many employees does Minervax have?
Minervax is in the 1-10 employee band.
How does Minervax's funding compare to other Biotechnology startups?
Minervax's latest round of $57.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Minervax Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Minervax is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.